PF-07934040 / Pfizer - LARVOL DELTA

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov) - P1 | N=330 | Recruiting | Sponsor: Pfizer | Trial completion date: Sep 2028 ➔ Jan 2029 | Trial primary completion date: Sep 2027 ➔ Jan 2028

IO biomarker • Trial completion date • Trial primary completion date • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • ALK • KRAS • ROS1

Official website of the Center for Drug Evaluation of the China Medical Products Administration (CDE) showed that Pfizer's Class 1 new drug Pan-KRAS inhibitor PF-07934040 tablets was approved for clinical use in China [Google translation] (bydrug.pharmcube.com) - "Overseas, Pfizer is conducting a Phase I clinical trial (NCT06447662) on PF-07934040 to evaluate the efficacy and safety of PF-07934040 alone or in combination with other targeted drugs in the treatment of advanced solid tumors (non-small cell lung cancer, colorectal cancer, pancreatic cancer) with KRAS gene mutations. The study plans to enroll 330 subjects, and the main indicators are expected to be completed in July 2027."

New trial • Trial status • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer